History

2013

Founded by Amir Jafri

January 2014

Terumo BCT, an industry-leading manufacturer of therapeutic apheresis equipment, and Immunicom enter into a strategic partnership

May 2014

Start of pre-clinical canine trial

December 2015

Completed a $5.5M Series A Preferred Stock financing

February 2016

The pre-clinical canine cancer trial ended, achieving 300 Immunopheresis treatments. Overall,  50-60%  of  the  canine patients  treated  were  observed  to  have  either a stable  disease or partial response. One canine experienced  a  complete  response  with  clearance  of  metastases.

December 2017

University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology

May 2018

The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer

August 2018

Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic

June 2019

First patient enrolled in a multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis as a treatment for patients with triple negative breast cancer

July 2019

Immunicom hosted the First Annual Global Immunopheresis Conference in Krakow, Poland

May 2020

The ImmunopheresisTM LW-02 column received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory triple negative breast cancer (TNBC)

July 2020

First patient enrolled in a clinical trial at Sheba Medical Center to investigate the outcomes of ImmunopheresisTM as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, triple negative breast cancer, renal cell carcinoma and non-small cell lung cancer

Get in touch today

Let’s talk about what we can achieve together

Learn more about
our team